Home > Publications database > Towards a reference cell atlas of liver diversity over the human lifespan. > print

001     305358
005     20251230103658.0
024 7 _ |a 10.1038/s41575-025-01114-3
|2 doi
024 7 _ |a pmid:41083606
|2 pmid
024 7 _ |a 1759-5045
|2 ISSN
024 7 _ |a 1743-4378
|2 ISSN
024 7 _ |a 1743-4386
|2 ISSN
024 7 _ |a 1759-5053
|2 ISSN
024 7 _ |a altmetric:182419722
|2 altmetric
037 _ _ |a DKFZ-2025-02102
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Taylor, Sarah A
|b 0
245 _ _ |a Towards a reference cell atlas of liver diversity over the human lifespan.
260 _ _ |a Basingstoke
|c 2026
|b Nature Publishing Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1767087368_1386402
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2026 Jan;23(1):97-109. doi: 10.1038/s41575-025-01114-3. Epub 2025 Oct 13
520 _ _ |a The goal of the Human Liver Cell Atlas (HLiCA) is to create a comprehensive map that defines the normal functions of diverse liver cell types and their spatial relationships over the human lifespan. This project fits within the goals of the Human Cell Atlas to create comprehensive reference maps of all human cells as a basis for both understanding human health and diagnosing, monitoring and treating disease. Through collection of samples from diverse individuals, data integration across technologies and overcoming liver-specific challenges for experimental methods, the HLiCA will map as many cell types and states as possible in healthy human livers from individuals across all ages and many ancestries. Establishing this HLiCA of healthy livers is a critical step to begin to understand perturbations in disease. The HLiCA will be available on an open-access platform to facilitate data sharing and dissemination. We expect that creation of the HLiCA will help to lay the foundation for new research initiatives to advance our understanding of liver disease, improve methods of tissue engineering, and identify novel prognostic biomarkers and therapies to improve patient outcomes. We describe key experimental and computational challenges to overcome in building the atlas and the potential impact of the atlas on disease research.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Bader, Gary D
|0 0000-0003-0185-8861
|b 1
700 1 _ |a MacParland, Sonya
|b 2
700 1 _ |a Mullen, Alan C
|0 0000-0002-4096-3106
|b 3
700 1 _ |a Andrews, Tallulah
|0 0000-0003-1120-2196
|b 4
700 1 _ |a Cuenca, Alex G
|b 5
700 1 _ |a DasGupta, Ramanuj
|0 0000-0001-9015-3729
|b 6
700 1 _ |a Gehring, Adam J
|b 7
700 1 _ |a Grün, Dominic
|0 0000-0002-3364-5898
|b 8
700 1 _ |a Guilliams, Martin
|b 9
700 1 _ |a Gulamhusein, Aliya
|b 10
700 1 _ |a Henderson, Neil C
|0 0000-0002-2273-4094
|b 11
700 1 _ |a Hirschfield, Gideon
|b 12
700 1 _ |a Huppert, Stacey S
|0 0000-0003-3977-8728
|b 13
700 1 _ |a Itzkovitz, Shalev
|0 0000-0003-0685-2522
|b 14
700 1 _ |a Jiang, Z Gordon
|b 15
700 1 _ |a Lauer, Georg M
|0 0000-0002-9792-4271
|b 16
700 1 _ |a McGilvray, Ian
|b 17
700 1 _ |a Mysore, Krupa R
|0 0000-0001-9890-5518
|b 18
700 1 _ |a Pirola, Carlos J
|0 0000-0001-8234-4058
|b 19
700 1 _ |a Quon, Gerald
|b 20
700 1 _ |a Rahbari, Mohammad
|0 P:(DE-He78)8757fd490dcfe2d6c4b1c2b126262468
|b 21
|u dkfz
700 1 _ |a Regev, Aviv
|b 22
700 1 _ |a Ricciuto, Amanda
|b 23
700 1 _ |a Scott, Charlotte L
|b 24
700 1 _ |a Sharma, Ankur
|b 25
700 1 _ |a Sookoian, Silvia
|0 0000-0001-5929-5470
|b 26
700 1 _ |a Tana, Michelle M
|0 0000-0002-3665-2735
|b 27
700 1 _ |a Teichmann, Sarah A
|b 28
700 1 _ |a Vallier, Ludovic
|0 0000-0002-3848-2602
|b 29
700 1 _ |a Vlachos, Ioannis S
|b 30
700 1 _ |a Wang, Bruce
|b 31
700 1 _ |a Zhen, Mei
|b 32
773 _ _ |a 10.1038/s41575-025-01114-3
|0 PERI:(DE-600)2493729-0
|n 1
|p 97-109
|t Nature reviews / Gastroenterology & hepatology
|v 23
|y 2026
|x 1759-5045
909 C O |p VDB
|o oai:inrepo02.dkfz.de:305358
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 21
|6 P:(DE-He78)8757fd490dcfe2d6c4b1c2b126262468
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2025
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-17
|w ger
915 _ _ |a DEAL Nature
|0 StatID:(DE-HGF)3003
|2 StatID
|d 2024-12-17
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NAT REV GASTRO HEPAT : 2022
|d 2024-12-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-17
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-17
915 _ _ |a IF >= 60
|0 StatID:(DE-HGF)9960
|2 StatID
|b NAT REV GASTRO HEPAT : 2022
|d 2024-12-17
920 1 _ |0 I:(DE-He78)D440-20160331
|k D440
|l Chronische Entzündung und Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D440-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21